文献速递神经免疫

达克利珠单抗治疗后出现伴嗜酸性粒细胞增多和全身症状的药物反应

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy.
PubMed 文献 · Neurology · 2018-06-22

报告2例多发性硬化女性患者分别接受2次和4次达克利珠单抗皮下注射后出现严重神经功能恶化和伴嗜酸性粒细胞增多和全身症状的药物反应(DRESS),临床表现、影像学和脑活检均符合DRESS诊断。

要点

  • 达克利珠单抗治疗后可发生DRESS,表现为神经功能恶化、血嗜酸性粒细胞增多和皮肤改变。
  • 脑活检显示嗜酸性粒细胞浸润脱髓鞘病灶,为不支持多发性硬化的非典型特征。
  • 达克利珠单抗因潜在严重副作用已在欧盟暂停使用。

核心结论

  • 神经功能恶化和DRESS是达克利珠单抗治疗的严重药物不良反应。
  • 早期诊断和治疗DRESS至关重要,因其与新发自身免疫病、肝衰竭等并发症相关,甚至可能致命。
  • 由于潜在严重副作用,达克利珠单抗近期在欧盟被暂停使用。

研究设计与样本

  • 病例报告,纳入2例接受达克利珠单抗治疗的多发性硬化女性患者,分别接受2次和4次皮下注射。
  • 报告包含临床、MRI和病理组织学数据。

主要发现

  • 2例患者均在达克利珠单抗治疗后出现暴发性神经功能恶化,伴血嗜酸性粒细胞增多和皮肤改变,均符合DRESS临床诊断标准。
  • MRI显示多发钆增强幕上和幕下病灶,累及基底节、中脑和小脑。
  • 脑活检显示明显的炎症浸润,包括大量嗜酸性粒细胞浸润脱髓鞘病灶,此特征对多发性硬化不典型但与DRESS相符。
  • 脑活检还可见大量浆细胞和提示血管炎的改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report on 2 women with multiple sclerosis (MS) who developed severe neurologic deterioration and a drug reaction with eosinophilia and systemic symptoms (DRESS) after treatment with 2 and 4 subcutaneous injections of daclizumab, respectively. METHODS: This report includes clinical, MRI, and histopathologic data. RESULTS: Daclizumab is a humanized monoclonal antibody that binds the interleukin-2 receptor. It was approved for the treatment of relapsing MS. DRESS is an immunologic reaction to various medications that is characterized by eosinophilia as well as cutaneous and visceral manifestations. Following daclizumab treatment, both patients showed fulminant neurologic deterioration along with blood eosinophilia and skin changes, and both fulfilled the clinical criteria for the diagnosis of DRESS. They presented with multiple gadolinium-enhancing supra- and infratentorial lesions, with lesions in the basal ganglia, mesencephalon, and cerebellum. Brain biopsies revealed a pronounced inflammatory infiltrate including numerous eosinophils infiltrating demyelinating lesions, a feature that is atypical for MS but compatible with DRESS. In addition, numerous plasma cells and changes reminiscent of vasculitis were evident. CONCLUSIONS: Neurologic deterioration and DRESS occurred as severe adverse drug effects of daclizumab treatment. Early diagnosis and treatment of DRESS are essential because it is associated with complications such as new autoimmune diseases and liver failure, and may even be lethal. Because of its potential serious side effects, daclizumab was recently suspended for use in the European Union.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Rauer S, Stork L, Urbach H, et al. Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. Neurology. 2018. PMID: 29934423. doi:10.1212/WNL.0000000000005854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。